

Metabolic Syndrome: the Silent Epidemic Driving Modern Health Risks

Zulfkar Qadrie

Department of Pharmacology, Government Medical College Baramulla

Humaira Ashraf

Department of Animal Nutrition, SKUAST-K, Srinagar, India

Mohd Altaf Dar

Department of Pharmacology, CT Institute of Pharmaceutical Sciences, PTU, Jalandhar Punjab

Abstract: Metabolic syndrome is a cluster of interconnected metabolic abnormalities, including central obesity, insulin resistance, hypertension, dyslipidemia, and elevated fasting glucose. Together, these factors significantly increase the risk of cardiovascular disease, type 2 diabetes mellitus, and overall mortality. The syndrome has become a growing global health concern, largely driven by rising rates of obesity, sedentary lifestyles, and poor dietary habits. Its prevalence continues to increase worldwide, affecting diverse populations and imposing substantial burdens on healthcare systems. This review article provides a comprehensive overview of metabolic syndrome, discussing its evolving definitions and diagnostic criteria used by leading health organizations. The pathophysiology is multifactorial, with insulin resistance and visceral adiposity playing central roles in driving systemic inflammation, oxidative stress, and hormonal imbalances. We also examine the clinical features and complications associated with metabolic syndrome, emphasizing its role as a precursor to cardiovascular events and diabetes. Current management strategies focus on lifestyle interventions, including dietary modification and increased physical activity, alongside pharmacological treatments targeting individual risk factors such as hypertension and dyslipidemia. The review underscores the importance of early detection and a multidisciplinary approach to care, involving healthcare providers, patients, and public health efforts to mitigate disease progression and improve outcomes. Future directions in research include exploring novel biomarkers and personalized therapies aimed at more effective prevention and treatment. Addressing metabolic syndrome is critical to reducing the global burden of chronic metabolic diseases and improving population health.

Keywords: Metabolic syndrome, insulin resistance, obesity, cardiovascular disease, type 2 diabetes

1. Introduction

Metabolic syndrome (MetS) is a complex and multifactorial condition characterized by a cluster of interrelated metabolic disturbances that collectively elevate the risk of developing cardiovascular diseases (CVD), type 2 diabetes mellitus (T2DM), and a range of other health complications. Unlike a single disease entity, MetS represents a constellation of risk factors that often occur together, significantly amplifying the likelihood of adverse health outcomes beyond what any one factor would pose individually. At the core of metabolic syndrome are key metabolic abnormalities: **abdominal obesity**, **elevated blood pressure**, **dyslipidemia** (which typically manifests as high triglyceride levels and low high-density lipoprotein [HDL] cholesterol), and **insulin resistance** or elevated fasting blood glucose [1]. Each of these components independently contributes to cardiovascular risk, but when combined, their synergistic effect accelerates the development of atherosclerosis, vascular damage, and metabolic dysfunction. The defining feature of abdominal obesity—excess fat accumulation around the waist—is particularly important. Visceral fat is metabolically active, releasing free fatty acids and inflammatory cytokines that exacerbate insulin resistance and promote systemic inflammation. This inflammatory milieu fosters endothelial dysfunction and lipid abnormalities, setting the stage for metabolic syndrome's progression [2].

The prevalence of metabolic syndrome has surged in recent decades, mirroring global trends in obesity and sedentary lifestyles. The adoption of Western dietary patterns—characterized by high consumption of processed foods, sugars, and unhealthy fats—combined with reduced physical activity has created an environment conducive to metabolic dysfunction. Consequently, metabolic syndrome has emerged as a “silent epidemic,” quietly affecting a growing proportion of the population worldwide. One of the challenges in addressing metabolic syndrome is that it often remains undiagnosed until serious complications arise, such as heart attacks, strokes, or overt diabetes. Individuals with metabolic syndrome may not experience obvious symptoms early on, and routine screening for the syndrome’s components is not always performed [3]. This delayed recognition contributes to preventable morbidity and mortality. Early identification of metabolic syndrome is crucial for initiating timely interventions aimed at reversing or managing the underlying metabolic disturbances. Lifestyle modifications, including dietary changes, increased physical activity, and weight loss, are the cornerstone of treatment and have demonstrated efficacy in improving insulin sensitivity, lipid profiles, and blood pressure control. Pharmacological therapies may be necessary to address persistent risk factors and prevent disease progression [4].

The public health implications of metabolic syndrome are profound. Given its association with some of the leading causes of death worldwide—cardiovascular disease and diabetes—effective prevention and management strategies are vital. Healthcare systems face increasing pressure from the growing burden of chronic metabolic diseases, highlighting the need for comprehensive approaches that combine clinical care with community-based interventions. Moreover, metabolic syndrome is not confined to adults alone. Rising rates of childhood obesity have led to the early onset of metabolic abnormalities in youth, increasing their lifetime risk of cardiometabolic diseases. This shift underscores the importance of preventive measures starting from a young age to combat the growing epidemic. Scientific research continues to unravel the complex pathophysiology of metabolic syndrome, including the roles of genetics, epigenetics, and environmental factors. Understanding these mechanisms paves the way for novel therapeutic targets and personalized medicine approaches that could improve outcomes [5].

2. Epidemiology

Metabolic syndrome (MetS) is a widespread health concern affecting approximately 20 to 30 percent of adults worldwide. However, its prevalence varies significantly across different populations, influenced by factors such as ethnicity, age, gender, and lifestyle habits. Understanding these variations is essential for tailoring prevention and management strategies to diverse communities. One consistent pattern is the increasing prevalence of MetS with advancing age. As individuals grow older, metabolic risk factors such as insulin resistance, hypertension, and dyslipidemia become more common, leading to a higher likelihood of developing the syndrome. Additionally, age-related changes in body composition, including increased visceral fat, contribute to this trend [6]. Ethnic and racial differences also play a role in MetS prevalence. For example, certain populations, such as Hispanic and South Asian groups, tend to exhibit higher rates of metabolic syndrome compared to Caucasian populations, even when controlling for body mass index (BMI). Genetic predisposition and cultural dietary patterns may partly explain these disparities. Lifestyle factors, particularly obesity and physical inactivity, are among the strongest contributors to the rising rates of MetS globally. The global obesity epidemic, fueled by calorie-dense diets and sedentary behaviors, directly increases the risk of developing metabolic abnormalities. Consequently, countries with high obesity rates also report elevated MetS prevalence [7]. In Western countries, the syndrome has reached epidemic proportions, imposing a substantial burden on healthcare systems due to its association with cardiovascular diseases, diabetes, and other chronic conditions. Notably, developing nations are witnessing a rapid rise in MetS cases as urbanization and lifestyle changes increase, creating a dual burden of infectious and chronic diseases. Overall, metabolic syndrome represents a growing global health challenge. Its rising prevalence underscores the need for targeted public health interventions and policies aimed at promoting healthier lifestyles, early detection, and effective management to curb its impact on populations worldwide [8].

3. Pathophysiology

The pathogenesis of metabolic syndrome (MetS) is intricate and multifactorial, involving a network of interrelated physiological disturbances. Central to this syndrome is **insulin resistance**, a condition where the body's cells become less responsive to insulin, impairing glucose uptake and metabolism. Insulin resistance leads to elevated blood glucose levels and compensatory hyperinsulinemia—an increase in circulating insulin as the pancreas attempts to overcome cellular resistance. This metabolic imbalance is a key driver behind many of the clinical features observed in MetS. One of the most significant contributors to insulin resistance and metabolic dysfunction is **visceral adiposity**, or the accumulation of fat around internal organs within the abdominal cavity [9]. Unlike subcutaneous fat, visceral fat is metabolically active and secretes various bioactive substances, including free fatty acids (FFAs) and pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF- α) and interleukin-6 (IL-6). Elevated levels of FFAs impair insulin signaling pathways in muscle and liver cells, further exacerbating insulin resistance. The pro-inflammatory cytokines released by visceral adipose tissue contribute to **systemic low-grade inflammation**, which is a hallmark of metabolic syndrome. This chronic inflammatory state promotes **endothelial dysfunction**, compromising the integrity and function of blood vessels. Endothelial dysfunction not only facilitates the development of hypertension but also predisposes individuals to atherosclerosis, increasing the risk of cardiovascular events [10-12].

Additional mechanisms implicated in the pathophysiology of MetS include **oxidative stress** and **mitochondrial dysfunction**. Oxidative stress arises from an imbalance between the production of reactive oxygen species (ROS) and the body's antioxidant defenses. Excess ROS can damage cellular components, including lipids, proteins, and DNA, further impairing insulin signaling and contributing to inflammation. Mitochondrial dysfunction, characterized by impaired energy metabolism and reduced capacity to manage oxidative stress, exacerbates these metabolic derangements. Hormonal imbalances involving adipokines—hormones secreted by adipose tissue—also play a critical role. Two key adipokines are **leptin** and **adiponectin**. Leptin, which regulates appetite and energy expenditure, is often elevated in obese individuals but is associated with leptin resistance, diminishing its beneficial effects. Adiponectin, on the other hand, has anti-inflammatory and insulin-sensitizing properties and is typically reduced in metabolic syndrome, worsening insulin resistance and vascular inflammation [13].

4. Clinical Features and Diagnosis

Metabolic syndrome (MetS) is diagnosed based on the presence of a specific cluster of metabolic risk factors. Various organizations have proposed diagnostic criteria, with the Adult Treatment Panel III (ATP III) guidelines being among the most widely used [14]. According to ATP III, a diagnosis of metabolic syndrome is made when an individual has at least three of the following five criteria:

- **Abdominal obesity:** Measured by waist circumference, with thresholds of greater than 102 cm (40 inches) in men and greater than 88 cm (35 inches) in women. This reflects excess visceral fat, a key contributor to metabolic dysfunction [14].
- **Elevated triglycerides:** A fasting triglyceride level of 150 mg/dL or higher indicates abnormal lipid metabolism and is linked to increased cardiovascular risk [14].
- **Reduced high-density lipoprotein (HDL) cholesterol:** HDL cholesterol, known as “good cholesterol,” is protective against heart disease. Levels below 40 mg/dL in men and below 50 mg/dL in women are considered low and contribute to the diagnosis [14].
- **Elevated blood pressure:** A blood pressure reading of 130/85 mmHg or higher, or the use of antihypertensive medication, reflects increased cardiovascular risk [14].
- **Elevated fasting glucose:** A fasting blood glucose level of 100 mg/dL or higher, or a previous diagnosis of type 2 diabetes, signals impaired glucose metabolism [14].

Other diagnostic criteria, such as those from the International Diabetes Federation (IDF), require the presence of central obesity as a mandatory component, accompanied by any two of the other factors. This highlights the critical role of abdominal fat in the syndrome's pathogenesis. Clinically, patients

with metabolic syndrome may not exhibit overt symptoms initially, making screening and awareness vital. Common features include increased waist circumference and signs related to hypertension or abnormal lipid levels identified during routine health evaluations. Early diagnosis allows timely intervention to manage individual risk factors and prevent progression to cardiovascular disease and diabetes, emphasizing the importance of regular screening in at-risk populations [14-16].

5. Complications and Risks

Metabolic syndrome (MetS) significantly elevates the risk of developing a wide range of serious health complications, primarily due to its combined impact on cardiovascular and metabolic systems. One of the most concerning outcomes is its strong association with **cardiovascular diseases (CVD)**, which remain the leading cause of morbidity and mortality worldwide. Individuals with metabolic syndrome are at a markedly increased risk for **coronary artery disease (CAD)**, characterized by the buildup of atherosclerotic plaques in the coronary arteries supplying the heart. This process can lead to angina, myocardial infarction (heart attack), and heart failure. The constellation of risk factors in MetS, including hypertension, dyslipidemia (high triglycerides and low HDL cholesterol), and insulin resistance, synergistically accelerates the development of atherosclerosis [16-18].

Stroke, another major cardiovascular event, is also more prevalent among those with metabolic syndrome. The same vascular changes that affect the coronary arteries can impair cerebral circulation, increasing the likelihood of ischemic strokes. Similarly, **peripheral vascular disease (PVD)**—characterized by narrowed blood vessels in the limbs—may result in pain, ulcers, and even limb loss in severe cases. Metabolic syndrome is also a major precursor to **type 2 diabetes mellitus (T2DM)**. Insulin resistance and impaired glucose metabolism often progress to overt diabetes, further compounding the risk for vascular complications and microvascular damage affecting the eyes, kidneys, and nerves [18-22].

Beyond cardiovascular and diabetic complications, metabolic syndrome is linked to several other conditions:

- **Non-alcoholic fatty liver disease (NAFLD):** This condition involves the accumulation of fat in the liver unrelated to alcohol use. NAFLD can progress to liver inflammation, fibrosis, and even cirrhosis, contributing to liver-related morbidity [23].
- **Polycystic ovary syndrome (PCOS):** A hormonal disorder affecting women of reproductive age, PCOS shares many features with metabolic syndrome, including insulin resistance and obesity, and is associated with increased cardiometabolic risk [24].
- **Chronic kidney disease (CKD):** Metabolic syndrome contributes to kidney damage through hypertension, diabetes, and vascular injury, increasing the risk of CKD and end-stage renal disease [25].
- **Certain cancers:** Emerging evidence suggests that metabolic syndrome may increase the risk of various cancers, including colorectal, breast, and pancreatic cancers, likely due to chronic inflammation, insulin resistance, and hormonal imbalances [26].

6. Management Strategies

Managing metabolic syndrome requires a comprehensive, multidisciplinary approach that targets the individual risk factors contributing to the condition. Because metabolic syndrome encompasses a cluster of metabolic abnormalities—such as abdominal obesity, insulin resistance, hypertension, and dyslipidemia—effective management involves addressing each component to reduce the overall risk of cardiovascular disease, type 2 diabetes, and other complications. The cornerstone of metabolic syndrome treatment is lifestyle modification [27-30]. This begins with dietary changes aimed at promoting weight loss and improving metabolic health. Dietary patterns such as the Mediterranean diet, rich in fruits, vegetables, whole grains, nuts, lean proteins, and healthy fats like olive oil, have been shown to reduce cardiovascular risk factors and improve insulin sensitivity. Similarly, the Dietary Approaches to Stop Hypertension (DASH) diet, which emphasizes fruits, vegetables, low-fat dairy,

and reduced sodium intake, is effective in lowering blood pressure and improving lipid profiles. Reducing the intake of processed foods, added sugars, and saturated fats is also critical to improve metabolic outcomes [30-32].

Increased physical activity is another vital component of lifestyle intervention. Regular aerobic exercise, such as brisk walking, swimming, or cycling, improves insulin sensitivity, aids in weight management, lowers blood pressure, and raises high-density lipoprotein (HDL) cholesterol. Resistance training is also beneficial for enhancing muscle mass and metabolic function. Guidelines generally recommend at least 150 minutes per week of moderate-intensity aerobic exercise combined with strength training on two or more days per week. For many individuals with metabolic syndrome, weight loss of 5 to 10 percent of body weight can substantially improve metabolic parameters [33]. Smoking cessation is essential because smoking exacerbates cardiovascular risk and worsens insulin resistance. Counseling, nicotine replacement therapy, and behavioral support can increase the likelihood of quitting successfully. When lifestyle changes alone are insufficient to control metabolic abnormalities, pharmacotherapy becomes necessary. The choice of medication depends on the specific risk factors present in each patient. For managing elevated blood pressure, antihypertensive drugs such as ACE inhibitors, angiotensin receptor blockers, calcium channel blockers, or diuretics may be prescribed. These agents not only lower blood pressure but some, like ACE inhibitors, also improve insulin sensitivity and offer kidney protection [33-35].

Dyslipidemia is treated primarily with statins, which reduce low-density lipoprotein (LDL) cholesterol and have proven cardiovascular benefits. In some cases, fibrates or omega-3 fatty acids may be added to address elevated triglycerides. For patients with elevated fasting glucose or impaired glucose tolerance, metformin is often the first-line medication due to its ability to improve insulin sensitivity and modestly reduce weight. Newer agents such as GLP-1 receptor agonists and SGLT2 inhibitors may be considered in select patients due to their cardiovascular benefits. Given the chronic nature of metabolic syndrome and the challenges associated with making sustained lifestyle changes, behavioral support is a crucial adjunct to medical treatment. Counseling by dietitians, exercise specialists, and psychologists can help patients develop realistic goals, overcome barriers, and maintain motivation. Structured programs that provide ongoing education, group support, and regular follow-up have demonstrated improved adherence and better health outcomes. Early intervention is essential to reduce long-term morbidity and mortality associated with metabolic syndrome. Identifying individuals at risk through screening programs enables timely implementation of lifestyle and pharmacologic measures, potentially preventing progression to overt diabetes and cardiovascular events. Healthcare providers play a critical role in educating patients, monitoring risk factors, and tailoring treatment plans to individual needs [36].

7. Future Directions and Research

Research into metabolic syndrome is rapidly advancing, focusing on identifying novel therapeutic targets and biomarkers to improve prevention and treatment. Traditional management strategies, while effective for many, often adopt a one-size-fits-all approach. However, the complex and multifactorial nature of metabolic syndrome calls for more personalized interventions tailored to an individual's unique genetic, metabolic, and environmental profile. Recent progress in **genomics** has revealed numerous genetic variants associated with susceptibility to metabolic syndrome and its components. Understanding how these genetic factors influence insulin resistance, obesity, lipid metabolism, and inflammation can help identify individuals at higher risk earlier and guide targeted therapies. For instance, genetic profiling may predict which patients will respond better to specific medications or lifestyle interventions [37]. In addition to genomics, the field of **metabolomics**—the comprehensive study of metabolites within cells and biological systems—offers insights into the biochemical pathways disrupted in metabolic syndrome. Metabolomic profiling can identify novel biomarkers that reflect disease severity, progression, and response to treatment. These biomarkers could be used for earlier diagnosis, monitoring therapeutic efficacy, and stratifying patients for personalized interventions. The integration of genomics and metabolomics with clinical data is driving the emergence of **personalized medicine** in metabolic syndrome care [38]. Personalized medicine aims to

tailor prevention and treatment plans based on an individual's specific risk factors, genetics, and lifestyle, potentially improving outcomes and minimizing side effects. Beyond molecular research, there is growing interest in exploring the role of the **gut microbiome** and its interaction with host metabolism. Alterations in gut bacteria have been linked to obesity, insulin resistance, and inflammation, suggesting that modulating the microbiome could become a future therapeutic strategy [38-40].

8. Conclusion

Metabolic syndrome has emerged as a significant public health challenge worldwide, fueled by lifestyle changes, increasing obesity rates, and complex metabolic disturbances. This syndrome—a cluster of interconnected risk factors including abdominal obesity, insulin resistance, hypertension, and dyslipidemia—substantially raises the likelihood of developing serious conditions such as cardiovascular disease and type 2 diabetes. Given its widespread prevalence and serious implications, metabolic syndrome demands urgent attention from both healthcare systems and society. Early diagnosis is critical to managing metabolic syndrome effectively. Many individuals remain unaware they have the condition until complications manifest, often in the form of heart attacks, strokes, or diabetes-related health issues. Regular screening for metabolic risk factors, especially in high-risk populations, can facilitate timely interventions. Identifying and addressing metabolic syndrome early allows for the implementation of lifestyle changes and pharmacological treatments that can slow or reverse disease progression. Comprehensive management involves a multidisciplinary approach that integrates lifestyle modification, pharmacotherapy, and behavioral support. Emphasizing healthy diets, regular physical activity, weight management, and smoking cessation can substantially improve metabolic parameters. When necessary, medications targeting hypertension, dyslipidemia, and hyperglycemia help mitigate risk. Behavioral counseling enhances patient adherence and fosters sustainable health habits. Addressing metabolic syndrome effectively requires collaboration among healthcare providers, patients, policymakers, and public health organizations. Public health initiatives aimed at promoting healthy lifestyles, increasing awareness, and improving access to preventive care are essential. Educational campaigns, community programs, and policy changes supporting healthier food environments and physical activity opportunities play crucial roles in curbing the epidemic.

9. References

1. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and infertility: an update. *International journal of adolescent medicine and health*. 2021 Jul 22;34(2):1-9.
2. Lihite RJ, Lahkar M, Das S, Hazarika D, Kotni M, Maqbool M, Phukan S. A study on adverse drug reactions in a tertiary care hospital of Northeast India. *Alexandria journal of medicine*. 2017 Jul 11;53(2):151-6.
3. Zehravi M, Maqbool M, Ara I. Correlation between obesity, gestational diabetes mellitus, and pregnancy outcomes: an overview. *International Journal of Adolescent Medicine and Health*. 2021 Jun 18;33(6):339-45.
4. Maqbool M, Bekele F, Fekadu G. Treatment strategies against triple-negative breast cancer: an updated review. *Breast Cancer: Targets and Therapy*. 2022 Jan 11:15-24
5. Rasool S, Maqbool M. An overview about *Hedychium spicatum*: a review. *Journal of Drug Delivery and Therapeutics*. 2019 Feb 15;9(1-s):476-80.
6. Zehravi M, Maqbool M, Ara I. Depression and anxiety in women with polycystic ovarian syndrome: a literature survey. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23;33(6):367-73.
7. Maqbool M, Gani I, Dar MA. Anti-diabetic effects of some medicinal plants in experimental animals: a review. *Asian Journal of Pharmaceutical Research and Development*. 2019 Feb 15;7(1):66-9.

8. Zehravi M, Maqbool M, Ara I. Polycystic ovary syndrome and reproductive health of women: a curious association. *International journal of adolescent medicine and health*. 2021 Apr 21;33(6):333-7.
9. Mohd M, Maqbool M, Dar MA, Mushtaq I. Polycystic ovary syndrome, a modern epidemic: an overview. *Journal of Drug Delivery and Therapeutics*. 2019 May 15;9(3):641-4.
10. Maqbool M, Fekadu G, Jiang X, Bekele F, Tolossa T, Turi E, Fetensa G, Fanta K. An up to date on clinical prospects and management of osteoarthritis. *Annals of Medicine and Surgery*. 2021 Dec 1;72:103077.
11. Majeed A, Bashir R, Farooq S, Maqbool M. Preparation, characterization and applications of nanoemulsions: An insight. *Journal of Drug Delivery and Therapeutics*. 2019 Mar 15;9(2):520-7.
12. Zehravi M, Maqbool M, Ara I. Healthy lifestyle and dietary approaches to treating polycystic ovary syndrome: a review. *Open Health*. 2022 May 2;3(1):60-5.
13. Maqbool R, Maqbool M, Zehravi M, Ara I. Menstrual distress in females of reproductive age: a literature review. *International journal of adolescent medicine and health*. 2021 Jul 22;34(2):11-7.
14. Ara I, Maqbool M, Fekadu G, Hajam TA, Dar MA. Pharmaceutical significance of *Nigella sativa* L., a wonder herb. *Journal of Applied Pharmaceutical Sciences and Research*. 2020;3(4):04-13.
15. Maqbool M, Nasir N, Mustafa S. Polycystic in ovarian syndrome and its various treatment strategies. *INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES*. 2018 Sep 1;5(9):8470-8.
16. Maqbool M, Zehravi M, Maqbool R, Ara I. Study of adverse drug reactions in pulmonary medicine department of a Tertiary care hospital, Srinagar, Jammu & Kashmir, India. *CELLMED*. 2021;11(2):8-1.
17. Ara I, Maqbool M, Bukhari B, Ara N, Hajam TA. Present status, standardization and safety issues with herbal drugs. *International Journal of Research in Pharmaceutical Sciences and Technology*. 2020 May 18;1(3):95-101.
18. Ara I, Maqbool M, Gani I. Reproductive Health of Women: implications and attributes. *International Journal of Current Research in Physiology and Pharmacology*. 2022 Nov 28:8-18.
19. Zehravi M, Maqbool R, Maqbool M, Ara I. To Identify Patterns of Drug Usage among Patients Who Seek Care in Psychiatry Outpatient Department of a Tertiary Care Hospital in Srinagar, Jammu and Kashmir, India. *Journal of Pharmaceutical Research International*. 2021 Jun 10;33(31A):135-40.
20. Maqbool M, Javed S, Bajwa AA. Assessment OF pain management IN postoperative cases using different scales and questionnaires. *INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES*. 2019 Jan 1;6(1):983-7.
21. Ara I, Maqbool M, Zehravi M. Psychic consequences of infertility on couples: A short commentary. *Open Health*. 2022 Jan 1;3(1):114-9.
22. Bashir R, Maqbool M, Ara I, Zehravi M. An In sight into Novel Drug Delivery System: In Situ Gels. *CELLMED*. 2021;11(1):6-1.
23. Zehravi M, Maqbool M, Ara I. Teenage menstrual dysfunction: an overview. *International Journal of Adolescent Medicine and Health*. 2022 Sep 19;35(1):15-9.
24. Ara I, Zehravi M, Maqbool M, Gani I. A review of recent developments and future challenges in the implementation of universal health coverage policy framework in some countries. *Journal of Pharmaceutical Research & Reports*. SRC/JPRSR-131. DOI: doi. org/10.47363/JPRSR/2022 (3). 2022;127.

25. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. *Indo American Journal Of Pharmaceutical Sciences*. 2018 Aug 1;5(8):8254-9.
26. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1;5(8):8163-+.
27. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1;5(8):8070-6.
28. Maqbool M, Ikram U, Anwar A. Adverse drug reaction monitoring and occurrence in drugs used in pulmonary disorders. *Indo American Journal Of Pharmaceutical Sciences*. 2018 Aug 1;5(8):8060-5.
29. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23;33(6):357-66.
30. Zehravi M, Maqbool M, Ara I. An overview about safety surveillance of adverse drug reactions and pharmacovigilance in India. *The Indian Journal of Nutrition and Dietetics*. 2021 Jul:408-18.
31. Maqbool M, Zehravi M. Neuroprotective role of polyphenols in treatment of neurological disorders: A review. *Interventional Pain Medicine and Neuromodulation*. 2021 Dec 31;1(1).
32. Maqbool M, Ara I, Gani I. The Story of Polycystic Ovarian Syndrome: A Challenging Disorder with Numerous Consequences for Females of Reproductive Age. *International Journal of Current Research in Physiology and Pharmacology*. 2022 Nov 28:19-31.
33. Maqbool M, Gani I. Utilization of statins in reducing comorbidities of diabetes mellitus: A systematic review. *Journal of Pharmacy Practice and Community Medicine*. 2018;4(4).
34. Maqbool R, Maqbool M, Zehravi M, Ara I. Acute neurological conditions during pregnancy and their management: a review. *International Journal of Adolescent Medicine and Health*. 2021 Aug 23;33(6):357-66.
35. Maqbool M, Tariq S, Amjad S. Prescribing practices in pediatrics and drug utilization studies promoting pediatric health. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1;5(8):8070-6.
36. Maqbool M, Naeem A, Aamer S. Diabetes mellitus and its various management strategies in practice. *Indo American Journal of Pharmaceutical Sciences*. 2018 Aug 1;5(8):8163-+.
37. Maqbool M, Shabbir W, Aamir S. Adverse events of blood transfusion and blood safety in clinical practice. *Indo American Journal Of Pharmaceutical Sciences*. 2018 Aug 1;5(8):8254-9.
38. Qadrie Z, Maqbool M, Dar MA, Qadir A. Navigating challenges and maximizing potential: Handling complications and constraints in minimally invasive surgery. *Open Health*. 2025 Feb 5;6(1):20250059.
39. Oral O, Maqbool M, Thapa P, Tatlibal P, Enser M. The potential impact of weight control management on metabolic health during healthy aging. *Global Translational Medicine*. 2025 Jan 13:4815.
40. Maqbool M, Oral O. Implications of hypothyroidism in females of reproductive age: a review of current literature.